ACADIA Pharmaceuticals To Present At Upcoming Investor Conferences

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming virtual investor conferences: Citi 15th Annual BioPharma Virtual ConferenceDate: Wednesday, September 9, 2020Panel: Emerging Therapies for...
Author:
Publish date:

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming virtual investor conferences:

Citi 15th Annual BioPharma Virtual ConferenceDate: Wednesday, September 9, 2020Panel: Emerging Therapies for Psychiatric Disorders at 1:30 p.m. Eastern Time

Morgan Stanley 18th Annual Global Healthcare ConferenceDate: Monday, September 14, 2020Fireside chat presentation: 3:45 p.m. Eastern Time

Cantor Virtual Global Healthcare ConferenceDate: Wednesday, September 16, 2020Fireside chat presentation: 11:20 a.m. Eastern Time

These conferences will all be held virtually. Live webcasts of the panel and presentations will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About ACADIA PharmaceuticalsACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA's development efforts are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, ACP-044 for pain management and an early-stage muscarinic receptor program. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005382/en/